The FDA administratively stayed its marketing denial order on Juul, determining that scientific issues unique to its application warrant additional review, according to an update on its website.
- Juul products are required to have FDA authorization to be legally marketed, the statement says
- “The stay and the agency’s review does not constitute authorization to market, sell, or ship JUUL products”
- The stay temporarily suspends the marketing denial order during the review but does not rescind it
- The FDA said that because Juul’s products don’t have marketing authorization, the company cannot legally market, ship or sell their products
- “The stay does ...
- “The stay does ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.